BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

Immunohistochemical expression of l1cam in endometrial carcinoma and its association with grade and stage of tumour-a cross sectional study in patients from a tertiary health care centre in south kerala

Authors:Dr. Renu K Regi*, Dr. Meeta Thomas
Int J Biol Med Res. 2026; 17(4): 8836-8841  |  PDF File  |  Full Text
DOI No.: 10.65048/ijbmr.2026.17.4.8836.1098

Abstract

Introduction: Endometrial carcinoma (EC) is one among the most common gynecological malignancies worldwide, with rising incidence and significant disease-related morbidity. Although conventional prognostic factors such as tumor grade, FIGO stage, and LVSI are widely used, they do not fully explain the biological heterogeneity and variable clinical outcomes observed among patients. L1CAM, a transmembrane glycoprotein mediating in cell migration and epithelial–mesenchymal transition, has emerged as a potential biomarker associated with tumor aggressiveness and poor prognosis in endometrial carcinoma. However, its clinicopathological significance requires further evaluation, particularly in relation to tumor grade, stage, and lymphovascular invasion. Aim: To estimate the frequency of L1CAM expression in endometrial carcinoma and to evaluate its association with clinicopathological parameters including histological type, tumour grade, tumor stage, myometrial invasion, lymphovascular invasion, and lymph node involvement. Methodology: This was a hospital-based observational study conducted on histopathologically confirmed cases of endometrial carcinoma. Formalin-fixed, paraffin-embedded tissue sections were analyzed using immunohistochemistry for L1CAM expression. Tumors were classified according to WHO histological criteria and staged as per the FIGO staging system. L1CAM positivity was defined based on membranous staining in tumor cells exceeding the established cutoff. Clinicopathological parameters including age, histological subtype, tumor grade, FIGO stage, and presence of lymphovascular invasion were recorded. Statistical analysis was conducted to assess associations between L1CAM expression and clinicopathological variables, with p-value <0.05 considered statistically significant. Result: L1CAM expression was observed in a subset of endometrial carcinoma cases and was significantly associated with higher tumor grade and advanced FIGO stage. A strong correlation was noted between L1CAM positivity and the presence of lymphovascular space invasion. Tumors expressing L1CAM were more frequently high-grade, non-endometrioid, and demonstrated aggressive pathological features. L1CAM expression showed a statistically significant association with adverse prognostic indicators, suggesting its role as a marker of tumor aggressiveness. Conclusion: L1CAM expression is significantly associated with higher tumor grade, advanced stage, and lymphovascular invasion in endometrial carcinoma. Its expression identifies a subgroup of tumors with aggressive biological behavior and poorer prognostic features. Incorporation of L1CAM immunohistochemistry into routine histopathological evaluation may improve risk stratification and to identify patients who are likely to benefit from closer surveillance and aggressive adjuvant therapy. L1CAM also holds promise as a potential therapeutic target in high-risk endometrial carcinoma.